Research ArticleClinical Studies
Hyperfractionated or Accelerated Hyperfractionated Re-irradiation with ≥42 Gy in Combination with Paclitaxel for Secondary/Recurrent Head-and-Neck Cancer
DIRK RADES, TOBIAS BARTSCHT, CHRISTIAN IDEL, STEVEN E. SCHILD and SAMER G. HAKIM
Anticancer Research June 2018, 38 (6) 3653-3656; DOI: https://doi.org/10.21873/anticanres.12641
DIRK RADES
1Department of Radiation Oncology, University of Lübeck, Lübeck, Germany
TOBIAS BARTSCHT
2Department of Hematology and Medical Oncology, University of Lübeck, Lübeck, Germany
CHRISTIAN IDEL
1Department of Radiation Oncology, University of Lübeck, Lübeck, Germany
3Department of Oto-Rhino-Laryngology and Head and Neck Surgery, University of Lübeck, Lübeck, Germany
STEVEN E. SCHILD
4Department of Radiation Oncology, Mayo Clinic, Scottsdale, AZ, U.S.A.
SAMER G. HAKIM
5Department of Oral and Maxillofacial Surgery, University of Lübeck, Lübeck, Germany
In this issue
Hyperfractionated or Accelerated Hyperfractionated Re-irradiation with ≥42 Gy in Combination with Paclitaxel for Secondary/Recurrent Head-and-Neck Cancer
DIRK RADES, TOBIAS BARTSCHT, CHRISTIAN IDEL, STEVEN E. SCHILD, SAMER G. HAKIM
Anticancer Research Jun 2018, 38 (6) 3653-3656; DOI: 10.21873/anticanres.12641
Hyperfractionated or Accelerated Hyperfractionated Re-irradiation with ≥42 Gy in Combination with Paclitaxel for Secondary/Recurrent Head-and-Neck Cancer
DIRK RADES, TOBIAS BARTSCHT, CHRISTIAN IDEL, STEVEN E. SCHILD, SAMER G. HAKIM
Anticancer Research Jun 2018, 38 (6) 3653-3656; DOI: 10.21873/anticanres.12641
Jump to section
Related Articles
- No related articles found.
Cited By...
- No citing articles found.